**5. Adherence to disease-modifying drugs**

Studies from literature have found a connection between the decreases in compliance for multiple sclerosis patients regarding to disease-modifying drugs [15–17]. In a study by Bruce et al. was demonstrated that MS patients which present an existing emotional disorder or anxiety disorder are approximately five times less probable to comply with disease-modifying therapy in comparison with MS patients that do not present psychiatric diagnosis positive [15]. A more favorable adheration in disease-modifying drugs was reported in patients with multiple sclerosis and secondary depression which received antidepressant therapy.
